Clinical Benefits of the Classification of Cardiovascular Patients based on the Polymorphisms of Natriuretic Peptide Receptor Genes

Jing Zhang Wang*, Xin-Hua Guo and Ting Zhang

Department of Medical Technology, Affiliated Hospital, College of Medicine, Hebei University of Engineering, Handan, China

*Corresponding author: Jing-Zhang Wang, Department of Medical Technology, Affiliated Hospital, College of Medicine, Hebei University of Engineering, 81# or 83# Cong Tai Road, Handan 056002, Hebei Province, P.R.China, Tel: +86-0310-8575130; Fax: +86-0310-8575130; E-mail: wangjingzhang1981@gmail.com

Rec date: Nov 27, 2014; Acc date: Dec 17, 2014; Pub date: Dec 27, 2014

Copyright: © 2014 Wang JZ. et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Natriuretic peptides (NPs NP) are supposed to be important biomarkers as well as therapeutic medicines for cardiovascular diseases, however, there are still some controversies blocking the clinical application of NPs. Especially, natriuretic peptide receptors (NPRs) greatly interfere with the indicative efficiency, therapeutic effectiveness, clinical dosage, and medication time of NPs. Herein, we propose that the classification of cardiovascular patients will effectively promote the clinical utilization of NPs as either biomarkers or medicines. Generally, NPs bind to natriuretic peptide receptor A and B (NPRA and NPRB) to activate cellular signalings, but natriuretic peptide receptor C (NPRC) is mainly responsible for the clearance of NPs. So, it is expected that high NPRs-sensitivity group includes individuals carrying the alleles that result in higher activity of NPRA and NPRB and lower activity of NPRC, while low NPRs-sensitivity group is the opposite. Theoretically, the classification will improve the diagnostic accuracy of NPs for cardiovascular patients, and personalized administration of NPs-related medicines will benefit more individuals in order to achieve both of the maximum therapeutic efficacy and the minimum side effects.

Keywords: Cardiovascular diseases; Natriuretic peptide; Natriuretic peptide receptor genes; Diagnosis; Therapy

Introduction

World widely speaking, cardiovascular impairment becomes one leading medical problem of the aged people, and efficient therapeutic medicines are especially needed by millions of the elders suffering from cardiovascular diseases [1,2]. Natriuretic peptides (NPs) are considered as important biomarkers as well as therapeutic medicines for cardiac disease, heart failure, coronary disease, and hypertension, because of their multiple biological effects (such as diuresis, natriuresis, vasodilation, and so on), convenient detection, and low cost [3-5]. NPs can serve as quantitative biomarkers for predicting cardiovascular diseases, and the concentration of serum NPs is helpful for evaluating the therapeutic efficacy for cardiovascular diseases [4-8]. Moreover, some NPs-based medicines, such as Nesiritide, Ularitide, Carperitide, and CDNP, have been used to treat cardiovascular diseases in some countries [9-12].

However, there are still many difficulties interfering with the clinical application of NPs. For example, the diagnostic accuracy of NPs for cardiovascular diseases is not very stable, and the therapeutic efficacy of NPs-related medicines is variable owing to some uncertain factors in vivo [3,13]. Moreover, although prolonged medication time and higher dosage of NPs are necessary for achieving the expected therapeutic efficacy in some cardiovascular patients, these measures may result in severer side-effects in other patients [3,14]. Therefore, the optimization of the drug dose and the medication time of NPs are emergently needed in clinics. Prospectively, the genetic variability in the natriuretic peptide pathway is critical for improving the clinical efficacy of NPs as either diagnosis biomarkers or therapeutic medicines.

Classify Cardiovascular Patients based on the Polymorphisms of Natriuretic Peptide Receptor Genes

Atrial natriuretic peptide (ANP), brain or B-type natriuretic peptide (BNP), and C-type natriuretic peptide (CNP) are three kinds of NPs [15,16]. Interestingly, it should be noted that the indicative and therapeutic efficacy of NPs are greatly dependent on the natriuretic peptide receptors (NPRs) in individuals [16,17]. Generally, the natriuretic peptide receptor A and B (NPRA and NPRB) are responsible for receiving the NP signalings, while the natriuretic peptide receptor C (NPRC) is responsible for the clearance of NPs [13,18-20]. NPRA, NPRB, and NPRC are encoded by the genes NPR1, NPR2, and NPR3, respectively, and the genetic variations of NPR1, NPR2, and NPR3 can result indifferent activity of NPRs and consequently influence the clinical efficacy of NPs in individuals [13,21].

The involvement of natriuretic peptide receptor genes in cardiovascular diseases

First, an eight nucleotides deletion in NPR1 gene is associated with the transcriptional activity of NPR1 gene and leads to the reduced activity of NPRA [21-24]. The single nucleotide polymorphism (SNP) G1023C of NPR1 alters the conformation and the activity of NPRA [21,25]. Several other variations in NPR1 gene influence not only the function of NPRA but also the concentration of ANP and BNP in vivo, significantly relevant to the pathogenesis of cardiovascular diseases [21,23,26-28]. Second, several SNPs in NPR2 significantly influence the concentration and the activity of NPRA, and NPR2 is an important candidate gene interfering with the therapeutic efficacy of NPs-related medicines [13]. The SNP C2077T of NPR2 gene is associated with the susceptibility and the severity of cardiovascular diseases [29]. Third, the SNP C–55A of NPR3 gene influences the activity of NPRC,
associating with the ANP concentration in vivo and the incidence of hypertension in individuals [21,30,31].

Therefore, the polymorphism of NPR genes regulate the nucleotide sequence, transcriptional efficiency, concentration, structure, and activity of NPRs in individuals, potentially influencing the concentration, clearance rate, and functional efficiency of NPs in vivo. Thus, cardiovascular patients with similar NPs concentration possibly show varied pathological characteristics when the NPR genes are differentiated among them, as a result the accuracy of NPs biomarkers are attenuated. Similarly, NPs-related medicines may have different therapeutic efficacy in cardiovascular patients with different NPR genotypes.

**Different NPs-sensitivity gradients of cardiovascular patients**

The above analysis indicates that analyzing the NPR genotypes may improve the clinical efficacy of NPs-based diagnosis and therapeutics for cardiovascular diseases. Briefly, we propose that it is necessary to classify the cardiovascular patients into different NP-sensitivity groups, from low NP-sensitivity to high NP-sensitivity, based on the polymorphisms of NPR genes. It has been shown that the activity of NPs is dependent on their binding to NPRA and NPRB, and that the clearance of NPs is promoted by NPRC [13,18-20], so it is expected that higher activity of NPRA and NPRB and lower activity of NPRC may lead to higher sensitivity to NPs, while lower activity of NPRA and NPRB and higher activity of NPRC may lead to lower sensitivity to NPs.

Henceforth, individuals can be divided into high NPs-sensitivity group and low NPs-sensitivity group. Theoretically, high NPs-sensitivity group includes individuals carrying the NPR alleles that result in higher activity of NPRA and NPRB as well as lower activity of NPRC, potentially leading to higher sensitivity to NPs in vivo. Whereas, low NPs-sensitivity group includes individuals carrying the NPR alleles that result in lower activity of NPRA and NPRB as well as higher activity of NPRC. Then, personalized medications and differentiated therapeutic procedures may benefit more cardiovascular patients aiming to improve the predictive efficacy and to achieve better therapeutic efficacy and fewer side effects.

**The current difficulties hindering the classification**

The methodologies that are suitable for detecting the polymorphisms of NPR genes include primer designing, PCR amplification, electrophoresis, DNA sequencing, and so on. However, the research focusing on the polymorphisms of NPR genes is still very limited, but the combined and systematic analysis may be necessary for obtaining more significant outcomes [21,34]. Another frequent difficulty disturbing the effectiveness of the analysis is that many studies employed a relatively small patient sample size, which may be not enough to give a convinced determination of some polymorphism sites, especially those sites of rare frequency [21]. So, it is expected that the international collaboration of researchers are required to investigate the synergistic effects of the polymorphic sites of NPR genes in sufficient amounts of individuals. This may greatly improve the understanding of the potential gene–gene interactions associating with the susceptibility to cardiovascular diseases and the pharmacogenetic response to NPs-based medicines. Besides, it is also suggested that analyzing rare polymorphism sites in some susceptible families is of great importance to explain the negative results as described previously.

**Discussion**

In brief, as concisely shown in Figure 1, the classification may improve the diagnostic accuracy of NPs for cardiovascular diseases. Although NPs are supposed to be efficient biomarkers for predicting cardiovascular diseases, individuals in low NPs-sensitivity group may have severer pathologies than those in high NPs-sensitivity group when the concentration of NPs is identical among them. Similarly, cardiovascular patients with similar pathologies may have significantly varied NPs levels in vivo between high NPs-sensitivity group and low NPs-sensitivity group. As a result, these problems may inevitably disrupt the diagnostic accuracy of NPs. Therefore, more attention should be paid to the clinical diagnosis of individuals in low NPs-sensitivity group, and other more suitable diagnostic methodologies rather than NPs biomarkers should be applied to the early diagnosis of their susceptibility to cardiovascular diseases.

The classification may be helpful for screening cardiovascular patients who are sensitive to NPs-related medicines. For patients in high NPs-sensitivity group, NPs-related medicines can be very robust; however, for those in low NPs-sensitivity group, NPs-related medicines may be ineffective, delay the therapy, and cause unnecessary economic burden. Consequently, it is better to administrate NPs-based medicines to patients in high NPs-sensitivity group at the earliest stage, while alternative medical approaches rather than NPs-based medicines should be applied to individuals in low NPs-sensitivity group. Further, in order to achieve maximum therapeutic efficacy as well as minimum side effects, individuals in low NPs-sensitivity group need higher dose of NPs-based medicines and longer medication time, while those in high NPs-sensitivity group need lower dose and shorter medication time.

Besides, because abnormal metabolism of NPs contributes to the development of cardiovascular diseases in a large number of individuals, the classification has great implications in the early prevention of cardiovascular diseases. In other words, the early screening of individuals who are very susceptible to cardiovascular diseases and the subsequent prevention measures are very important to decrease the severity and mortality of cardiovascular patients. For
this aim, analyzing the genetic variations of NPRs will certainly contribute to the early prevention of cardiovascular diseases [18,21,30].

Conclusion

Because NPR genes play important roles in the diagnosis and therapy of cardiovascular diseases, the classification of cardiovascular patients based on the polymorphisms of NPR genes will have multiple clinical benefits, which makes it possible to administrate personalized medical approaches for cardiovascular patients with different NPR genotypes. The classification may improve the diagnostic efficiency of NPs, screen individuals sensitive to NPs-based therapy, and guide the clinical administration of NPs-related medicines. In summary, on the basis of the argument that prevention is better than cure in geriatric medicine [35], the classification will especially contribute to the early diagnosis of cardiovascular diseases and the administration of NPs-related medicines.

Acknowledgments

Supported by the findings from Hebei Science and Technology Department (No.12276104D-58) and Hebei Educational Committee (No.QNZ20131051) of China.

References

1. Wang JZ, Li SR, Li YL, Zhang YZ, Zhang T, et al. (2013) Could P181 help us conquer essential hypertension at an earlier stage? A promising early-diagnostic biomarker and its therapeutic implications for the disease. Med Hypotheses 81:931-935.

2. Basile G, Crucitti A, Cucinotta MD, Lacquanti A, Catalano A, et al. (2014) Serum levels of Apelin-36 are decreased in older hospitalized patients with heart failure. Eur Geriatr Med 5: 242-247.

3. Wang P, Luan X, Wang G, Liu W, Zhang J, et al. (2013) Atrial natriuretic peptide and regulation of vascular function in hypertension and heart failure: implications for novel therapeutic strategies. J Hypertens 31: 1061-1072.

4. Ding JH, Chang YS (2012) Atrial natriuretic peptide: a possible mediator involved in dexamethasone’s inhibition of cell proliferation in multiple myeloma. Med Hypotheses 79: 207-209.

5. Ma L, Xiang X (2011) Atrial natriuretic peptide/natriuretic peptide receptor A (ANP/NPRA) signaling pathway: a potential therapeutic target for allergic asthma. Med Hypotheses 77: 832-833.

6. Mutschler J, Kief F (2011) The natriuretic peptide system as a possible therapeutic target for stress-induced obesity. Med Hypotheses 76: 388-390.

7. Pereira NL, Lin D, Pelleymonuter L, Moon I, Stillig G, et al. (2013) Natriuretic peptide receptor-3 gene (NPRP3) nonsynonymous polymorphism results in significant reduction in protein expression because of accelerated degradation. Circ-Cardiovasc Gene 6:201-210.

8. Bellii N, Roussel R, Jaziri R, Chatellier G, Lievre M, et al. (2006) Effect of polymorphism N521D of the NPRC gene (receptor of natriuretic peptides clearance) on albuminuria and arterial pressure in patients with diabetes of type 2 with a high vascular risk (DIABHYCAR study). Diabetes Metab 32:S51.

9. Lanfear DEI (2010) Genetic variation in the natriuretic peptide system and heart failure. Heart Fail Rev 15: 219-228.

10. Vassalle C, Andreassi MG (2009) Genetic polymorphisms of the natriuretic peptide system in the pathogenesis of cardiovascular disease: what lies on the horizon? Clin Chem 55: 878-887.

11. Nakayama T, Soma M, Takahashi Y, Rehemudula D, Kamatsuke S, et al. (2000) Functional deletion mutation of the 5'-flanking region of type A human natriuretic peptide receptor gene and its association with essential hypertension and left ventricular hypertrophy in the Japanese. Circ Res 86:841-845.

12. Rubattu S, Calvieri C, Pagliaro B, Volpe M (2013) Atrial natriuretic peptide receptor gene: Possible association with essential hypertension. J Am Coll Cardiol 48: 499-505.

13. Usami S, Kishimoto I, Saito Y, Harada M, Kuwahara K, et al. (2008) Association of genetic variation with gene expression and protein function of the natriuretic peptide system in the pathogenesis of cardiovascular disease: the PROTECT multicenter randomized controlled dose-finding study. Eur J Clin Investig 38: 388-393.

14. Hayek S, Nemer M (2011) Cardiac natriuretic peptides: from basic discovery to clinical practice. Cardiovasc Ther 29: 362-376.

15. Poortvliet RKE, de Craen AJM, Guuskello J, de Ruijter W (2013) Change in N-terminal pro B-type natriuretic peptide levels in the oldest old: The Leiden 85-plus Study. Eur Geriatr Med 4, Supplement 1: S160-S161.

16. Abrahamsen JF, Haaglund C, Nilsen RM, Ranhoff AH (2014) Predictors for return to own home and being alive at 6 months after nursing home intermediate care following acute hospitalization. Eur Geriatr Med 5:108-112.

17. Holmström A, Petzold M, Fu MLX (2013) Recent evaluation of prognostic significance of NT-proBNP in a 5-year follow-up study assessing all-cause mortality in elderly patients (>75 years) admitted to hospital due to suspect heart failure. Eur Geriatr Med 4:8-14.

18. Holmström A, Sigurjonsdottir R, Hammarsten O, Petzold M, Gustafsson D, et al. (2013) An integrated multiple marker modality is superior to NT-proBNP alone in prognostic prediction in all-cause mortality in a prospective cohort of elderly heart failure patients. Eur Geriatr Med 4: 365-371.

19. Fanoraw GC1 (2003) B-type natriuretic peptide: spectrum of application. Nesiritide (recombinant BNP) for congestive heart failure: a phase II, multicentre randomized controlled dose-finding study. J Clin Pharm Ther 38: 388-393.

20. Nakayama T, Soma M, Mizutani Y, Xinjuan X, Honye J, et al. (2002) A novel missense mutation of exon 3 in the type a human natriuretic peptide receptor gene: Possible association with essential hypertension. J Am Coll Cardiol 48: 499-505.

21. Usami S, Kishimoto I, Saito Y, Harada M, Kuwahara K, et al. (2008) Common variations in noncoding regions of the human natriuretic peptide receptor A gene have quantitative effects. Hum Genet 112:62-70.

22. Garg R, Pandey KN (2005) Regulation of guanylyl cyclase/natriuretic peptide receptor-A gene expression. Peptides 26: 1009-1023.

23. Vassalle C, Andreassi MG, Proterna C, Fontana M, Zyw L, et al. (2007) Influence of ScaI and natriuretic peptide (NP) clearance receptor polymorphisms of the NP System on NP concentration in chronic heart failure. Clin Chem 53: 1886-1890.
29. Wang L, Lu L, Zhang F, Chen Q, Shen W (2010) Polymorphisms of beta-adrenoceptor and Natriuretic Peptide Receptor Genes Influence the Susceptibility to and the Severity of Idiopathic Dilated Cardiomyopathy in a Chinese Cohort. J Card Fail 16:36-44.

30. Sarzani R, Dessi-Fulgheri P, Salvi F, Serenelli M, Spagnolo D, et al. (1999) A novel promoter variant of the natriuretic peptide clearance receptor gene is associated with lower atrial natriuretic peptide and higher blood pressure in obese hypertensives. J Hypertens 17:1301-1305.

31. Sarzani R, Strazzullo P, Salvi F, Iacone R, Pietrucci F, et al. (2004) Natriuretic peptide clearance receptor alleles and susceptibility to abdominal adiposity. Obes Res 12: 351-356.

32. Tsezou A, Karayannis G, Giannatou E, Papanikolaou V, Triposkiadis F (2008) Association of renin-angiotensin system and natriuretic peptide receptor A gene polymorphisms with hypertension in a Hellenic population. J Renin Angiotensin Aldosterone Syst 9: 202-207.

33. Lynch AI, Claas SA, Arnett DK (2009) A review of the role of atrial natriuretic peptide gene polymorphisms in hypertension and its sequelae. Curr Hypertens Rep 11: 35-42.

34. Bergeault K, Bertisch C, Merdinoglu D, Walter B (2010) Low level of polymorphism in two putative NPR1 homologs in the Vitaceae family. Biol Direct 5: 9.

35. Zhu BF, Chen HL, Shen JH, Xing JL, Chen JR (2014) The relationship between patients’ age and prognosis outcome after cardiopulmonary resuscitation in adults: A meta-analysis. Eur Geriatr Med 5: 323-329.